Exhibit 10.2


 


Confidential Materials omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]




 





LICENSING, MANUFACTURING

AND SUPPLY AGREEMENT


 


This Licensing, Manufacturing and Supply
Agreement (the “Agreement”) is being entered into as of the 12th day of October 2011 (the “Effective
Date”), by and between INNOCOLL PHARMACEUTICALS, LIMITED, an Irish Corporation (collectively, with its Affiliates “Innocoll”) whose
principal office is Midlands Innovation and Research Centre, Dublin Road, Athlone, Co. Westmeath, Ireland (or “Innocoll”) and
Pioneer Pharma Co. Ltd., offices located at Suite A-C 18F, HuDong Finance Building, No. 1128, Xiang Yin Road, Shanghai, China (“PIONEER”)


 


Preliminary Statements


 


WHEREAS, Innocoll has developed the
Product and desires to grant to PIONEER the exclusive right to distribute and sell the Product in the Territory in the Field (as
each is defined below);


 


WHEREAS, PIONEER is willing to act as
Innocoll’s distributor for the Product in the Territory in the Field; and


 


WHEREAS, Innocoll and PIONEER desire
to enter into this Agreement to set forth the terms and conditions of such distribution right and all other rights and obligations
of the parties relating thereto.


 


NOW, THEREFORE, the parties agree as
follows:


 


Terms and Conditions


 


		1.	Defined Terms:



 


		1.1	Affiliates shall mean, with respect to either party, those entities controlled by, in control
of, or under common control with such party. A corporation or non-corporate business entity shall be regarded as in control of
another corporation or business entity (i) if it owns or directly or indirectly controls a majority of the voting stock or
other ownership interest of the other entity, or (ii) in the absence of the ownership of a majority of the voting stock or
other ownership interest of such entity, if it possesses, directly or indirectly, the power to direct or cause the direction of
the management and policies of such corporation or non-corporate business entity, as applicable.



 


		1.2	Field shall mean adhesion barrier and any other indication approved by EU regulatory authorities
and the SFDA.



 


		1.3	Product shall mean product(s) identified in Exhibit A



 


		1.4	Territory shall mean The People’s Republic of China, including the territories of
Hong Kong, Macau and Taiwan.



 


		2.	Appointment of Exclusive Distributor



 


		2.1	Innocoll hereby appoints PIONEER as its sole and exclusive distributor to market, sell, advertise,
promote and distribute, directly or through its Affiliates the Product in the Field in the Territory. PIONEER hereby accepts such
appointment.



 




    	 



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		2.2	Innocoll represents and warrants to PIONEER that Innocoll has not entered into any other agreements,
written or oral, with any third party permitting the sale or distribution of the Product in the Field in the Territory, and Innocoll
covenants and agrees that during the Term, Innocoll will not enter into any such agreement or itself, directly or indirectly, sell
or distribute the Product or any product that competes directly with the Product in the Territory. PIONEER covenants and agrees
that during the Term it will not itself or cause or permit any Affiliate to enter into an agreement with a third party to, promote,
market or sell in the Territory a product that competes directly with the Product.



 


		3.	Manufacture and Supply of Product



 


		3.1	Forecasts. At the beginning of each calendar month during the Term, PIONEER shall provide
Innocoll with a non-binding, good faith written forecast of PIONEER’S expected requirements for Product during the following
*** period (the “Forecast”). Notwithstanding the first sentence of this Section 3.1, the first *** period included
in each Forecast shall constitute a firm purchase order and binding commitment.



 


		3.2	Orders. PIONEER shall place binding orders for Product by written or electronic purchase
order (or by any other means agreed to by the parties) to Innocoll. Innocoll shall acknowledge and accept or reject any PIONEER
purchase order in writing within ten (10) days of receipt. Innocoll shall not refuse to accept any order in an amount equal
to or less than the most recent Forecast, unless Innocoll has indicated upon receiving a Forecast that it will not be able to meet
this requirement. All such purchase orders shall be irrevocable. Purchase orders shall set forth the desired date of delivery with
respect to the Product ordered and shall be placed at least *** prior to such desired date of delivery. All Product ordered by
PIONEER under this Agreement shall be delivered on or before the delivery date set forth in the applicable purchase order.



 


		3.3	Innocoll will manufacture the Products exclusively for PIONEER in accordance with the Specifications
and in compliance with all relevant legal and regulatory requirements.



 


		3.4	Shipment. Innocoll shall deliver the Product, ***, or other location as Parties might agree
upon from time to time (the “Shipping Point”). Innocoll shall ship all Product in accordance with the instructions
***. A Certificate of Analysis (“COA”) specific to testing of each lot/batch, must accompany each shipment.
Innocoll shall maintain a copy of each such COA in compliance with cGMP/QSR. Innocoll shall provide a duplicate copy of the COA
to PIONEER, upon PIONEER’S request.



 


		3.5	Inspection and Acceptance. PIONEER shall have the right, at its sole discretion, to inspect
each and every shipment of the Product. PIONEER shall have fifteen (15) days from receipt of each shipment of Product to visually
inspect the shipment (Inspection Period). PIONEER may reject a shipment (or portion thereof) of Product if any
one or more units contained therein fail to conform to the Specifications, by providing Innocoll written notice of such rejection
prior to the end of the Inspection Period. PIONEER may then return all or a portion of the shipment of Product to Innocoll and
Innocoll shall either supply replacing Product or a full refund at the discretion of Pioneer. In addition to the foregoing, for
any Product for which the defect identified by PIONEER is a latent defect that could not reasonably be detected upon visual inspection,
PIONEER shall have a



 



    	2



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    




 


period of
*** from the date of identification of such latent defect to return any such Product to Innocoll and Innocoll shall either supply
replacing Product or a full refund at the discretion of Pioneer. Should any Chinese government body such as customs or SFDA deem
the shipment to be non-compliant and therefore refuse the Product access to the Chinese market, this shall be deemed a latent defect
as mentioned above.


 


		3.6	Upon shipment of Products, Innocoll shall invoice PIONEER. Payment by PIONEER will be due in full
ninety (90) days after receipt of invoice.



 


		4.	Supply Prices and Additional Consideration



 


Product Supply Prices and
Additional Consideration are set out in Exhibit B which is incorporated herein by reference.


 


		5.	Minimum Purchase Requirements



 


From *** to ***, PIONEER will
purchase Products from Innocoll in an amount as set out on Exhibit C hereto (“Minimum Purchase Requirement”).


 


		6.	Complaints



 


PIONEER will inform Innocoll
immediately of any complaints related to the Products and will liaise with Innocoll in investigating the possible causes and agree
on any remedial plans of action.


 


		7.	Batch Recall



 


Innocoll, in its capacity
as responsible manufacturer of the Products, shall be responsible for any batch recall of Products from the market and co-ordinate
the same. In the event any governmental authority or agency requests a recall or takes similar action in connection with the Products,
or in the event that PIONEER determines an event or incident has occurred which may result in the need for a recall or a market
withdrawal, PIONEER will inform Innocoll by telephone or facsimile within 24 hours and the parties shall agree on an appropriate
course of action. Innocoll shall bear the expense of any recall resulting from breach of its obligations hereunder or from negligent
manufacture, packaging or shipment of the Products by it. In all other cases, PIONEER shall bear the expense of any recall.


 


		8.	Auditing



 


		8.1	During normal business hours, Innocoll shall provide access to its premises to PIONEER to permit
audits of the relevant documents and facilities by PIONEER. PIONEER shall be entitled to *** during the Term.



 


		8.2	Innocoll will ensure that any material deficiencies highlighted during any audit by PIONEER or
Regulatory Bodies will be dealt with as soon as is practically possible following receipt of an official signed Audit Report from
PIONEER.



 




    	3



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		9.	PIONEER Obligations



 


		9.1	PIONEER shall be responsible for compiling, submitting and maintaining the Product registrations,
and all associated costs. Innocoll shall provide required Products free of charge for registration and clinical trial in the Territory
and provide relevant and available information and documentation to support the Product registrations in English to PIONEER and
PIONEER shall be responsible for all required translations. PIONEER shall be responsible for obtaining Product registration and
will bear all associated costs.



 


		9.2	PIONEER shall launch the Product(s) within *** of receiving Regulatory Approval. If PIONEER
fails to launch the product within ***, the Product rights will revert to Innocoll.



 


		9.3	PIONEER shall sell and distribute the Product in the Territory under the original trade-marks and
packages of Innocoll or under any modified trademarks or packages agreed by the Parties.



 


		9.4	PIONEER shall provide at its own expense all staff and facilities necessary for the operation of
the distributorship and the fulfillment of the terms of this Agreement.



 


		9.5	PIONEER shall handle and store the Products securely and with all due skill care and attention
and shall not take any step to alter the condition of any of the Products from that in which the Products are delivered by Innocoll.



 


		9.6	At the request of Innocoll, PIONEER shall receive employees and representatives of Innocoll and
shall render to them all reasonable facilities for investigating conditions of trade and to visit customers in the Territory. Each
party shall bear their own costs relating to such visits.



 


		9.7	PIONEER shall in good faith prepare and submit to Innocoll on or before January 15th
in each year a detailed marketing plan and budget (“the Plan”) for the promotion of the Products for the immediately
succeeding calendar year.



 


		9.7.1	In the event that the Plan is agreed upon by Innocoll and PIONEER, PIONEER shall use all reasonable
endeavours to ensure that it conforms to the Plan during the relevant calendar year.



 


		9.7.2	PIONEER shall keep Innocoll informed of competition experienced in the Territory and when so requested
by Innocoll provide information on marketing activities and competitive products in the Territory.



 


		9.7.3	PIONEER shall prepare all advertising promotional and marketing material for the Products and submit
the same to Innocoll for approval. On receipt of such approval (which shall not be unreasonably withheld or delayed) PIONEER
shall produce all such approved material at PIONEER’S expense.



 


		9.8	PIONEER shall purchase the agreed annual minimum quantities defined in Exhibit C.



 


		9.9	PIONEER has or will have and will maintain in force a product liability insurance which is covering
any and all liabilities of PIONEER relating to the Products.



 




    	4



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		10.	Innocoll Obligations



 


		10.1	Innocoll shall comply in all material respects with all laws, rules and regulations applicable
to the design, manufacture, labelling, packaging, storage and handling of the Product, including maintaining qualified manufacturing
and quality facilities and/or procedures. Innocoll shall ensure that all third-party manufacturers of any raw materials for the
Product comply in all material respects with all laws, rules and regulations applicable to the design, manufacture, labelling and
packaging of the Product in the Territory. Without limiting the generality of the foregoing, Innocoll (and all third-party manufacturers
of any raw materials for Product) shall implement such quality control systems and procedures as shall be appropriate to ensure
compliance with the requirements of ISO and cGMP/QSR, which are applicable to Innocoll or such third-party manufacturer as the
manufacturer and supplier of the Product. Innocoll shall allow reasonable access to its records, manufacturing facilities, and
its third-party manufacturers’ manufacturing facilities and records (if applicable) to allow any Regulatory Authority
to conduct full compliance audits or inspections relating to the Product. Innocoll and any third party manufacturer shall ensure
that the Products are manufactured in strict compliance with the Specifications.



 


		10.2	Innocoll hereby undertakes to sell the Products to PIONEER at the prices determined in accordance
with Exhibit B hereof and on terms and conditions in accordance with the provisions hereof.



 


		10.3	Innocoll will without delay approve as appropriate the material for the advertising promotion and
marketing of the Products in the Territory as submitted by PIONEER.



 


		10.4	***



 


		(i)	***



 


		(ii)	***



 


		(iii)	***



 


		10.5	***



 


		10.6	Innocoll has and will maintain in force a product liability insurance which is covering any and
all liabilities of Innocoll relating to the Products.



 


		11.	Confidentiality Obligations



 


		11.1	Each party agrees to maintain during the term of this Agreement and for a period of *** thereafter
the strictest confidence with regard to the confidential and/or proprietary information, in whatever medium, relating to the Products
and their manufacture, and any other information disclosed to it under this Agreement by the other party and proprietary to it
or its affiliates or any third party contract partners (the



 




    	5



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


“Confidential
Information”). Neither party shall directly nor indirectly pass on the Confidential Information to others nor use it
for any purpose not mentioned in this Agreement. Each party shall have the right to disclose the other party’s Confidential
Information to its employees or advisors who need this knowledge for the purposes authorized herein. To the extent that a party
discloses Confidential Information to an employee or advisor, such party will be responsible for any failure by such persons or
entities to hold such information in confidence or use such information solely for the purposes of this Agreement.


 


		11.2	The obligations of confidentiality and use restrictions set forth herein above will not apply to
the following information:



 


		11.2.1	information that is or becomes publicly known or available by publication, commercial use or otherwise
without breach of this Agreement by the receiving party;



 


		11.2.2	information that the receiving party rightfully receives from a third party without a restriction
on disclosure,



 


		11.2.3	information that must be disclosed pursuant to governmental and regulatory requirements (including
Certification Audits);



 


		11.2.4	information that is independently developed by employees of the receiving party who have not had
access to the Confidential Information; or



 


		11.2.5	information that is known by the receiving party at the time of receipt.



 


		12.	Proprietary Rights



 


		12.1	All Know-how (all manufacturing and technical data, instructions, specifications and experiences
regarding the Products as well as test methods developed) documented in the Specifications is owned by Innocoll (“Innocoll
Know-How”). Pioneer shall have a limited, royalty-free license to use the Innocoll Know-How in accordance with and for
the term of this Agreement.



 


		12.2	Innocoll represents and warrants that Innocoll’s manufacturing methods do not infringe any
third party’s proprietary rights. Innocoll will indemnify and hold harmless PIONEER for any and all claims arising out of
or based on claims related to the intellectual property rights underlying such methods.



 


		13.	Warranties and Liability



 


		13.1	Innocoll shall be responsible for all claims related to the Product to the extent arising from
***. PIONEER shall be responsible for all claims related to the Product to the extent arising from: ***.



 




    	6



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		14.	Indemnities



 


		14.1	As soon as a party becomes aware of the possibility of a claim involving indemnification under
this article, the indemnified party shall give the indemnifying party prompt notice in writing and shall permit the indemnifying
party to have control over and conduct the defense of such claim or suit. The indemnified party agrees to provide all reasonable
information and assistance to the indemnifying party in such defense.



 


		14.2	Innocoll shall indemnify and hold PIONEER harmless against ***.



 


		14.3	PIONEER shall indemnify and hold Innocoll harmless against ***.



 


		15.	Term and Termination



 


		15.1	This Agreement shall become effective on the Effective Date and shall continue for ten (10) years.



 


		15.2	Each party shall be entitled to terminate the Agreement with immediate effect for material cause.
“Material cause” shall include, but not be limited to, the following:



 


		15.2.1	If PIONEER fails to pay for the Products within the time set forth in Clause 3.6 above, if
PIONEER should fail to meet the minimum purchase obligations as specified in Exhibit C, or if PIONEER is otherwise in breach of
its obligations under this Agreement; then Innocoll, may, at its option, cancel this Agreement upon *** prior written notice to
PIONEER unless PIONEER cures such breach and any intervening breach within such *** period.



 


		15.2.2	If Innocoll is in breach of its obligations under this Agreement then PIONEER may at its option
cancel this Agreement upon *** prior written notice to Innocoll unless Innocoll cures such breach and any intervening breach within
such *** period.



 


		15.2.3	If the other party files a petition in bankruptcy, or applies for a consent to the appointment
of a receiver or trustee or suffers or permits the entry of an order adjudicating it to be bankrupt or insolvent.



 




    	7



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		15.3	In an event stipulated under 15.2.2 above, where PIONEER cancels this Agreement and Innocoll fails
to cure the breach: ***.



 


		15.4	Upon termination of this Agreement, only accounts payable and/or receivable and liabilities provided
for under this Agreement shall remain in effect and neither party shall be entitled to any costs compensation or damages whatsoever
sustained resulting from, or arising out of or alleged to have been sustained, to have resulted from, or to have arisen out of
such termination.



 


		15.5	Upon cancellation or expiration of this Agreement, PIONEER shall return all data, prospectuses
and materials including, without limitation, all copies of test results and other data accumulated, advertising and promotional
materials samples and instruments relating to the Products and in such event the distribution rights and all other rights granted
to PIONEER under this Agreement shall revert to Innocoll and PIONEER shall not make further use of such technical information or
disclose same.



 


		15.6	Upon cancellation or expiration of this agreement, PIONEER shall immediately initiate the transfer
of the Product registration to Innocoll or its designee.



 


		15.7	The termination of this Agreement shall not release either party from the obligation to make the
payment of any sum then owing, and it shall not release PIONEER from its obligation to pay Innocoll for all the Products ordered
and received, and Innocoll to deliver all the Products ordered which have been previously accepted by Innocoll as per section 3.2.



 


		16.	Miscellaneous Provisions



 


		16.1	In case of force majeure, official orders, strike or lockout or similar hindrances which the parties
are unable to avert, the parties shall be released for the duration of such hindrance from the contractual obligations which they
are prevented from performing; provided however that if such suspension shall continue in excess of one hundred eighty (180) days
the parties shall meet and attempt to arrive at a mutually acceptable compromise within the spirit and intent of this Agreement.
In the event of shortage of production or supply of the Products for any reason Innocoll reserves the right to allocate its supplies
of the Products to itself and such other distributors or customers as it deems equitable.



 


		16.2	This Agreement shall be governed by and construed in accordance with the substantive provisions
of Singapore law. Place of jurisdiction and forum for any disputes shall be Singapore.



 


		16.3	If individual provisions or rules of this Agreement are invalid or become invalid, the parties
hereby agree that this shall not affect the validity of the remainder of the terms and provisions. The parties undertake to replace
the invalid provisions by others which come closest to the effect originally intended.



 




    	8



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


		16.4	This Agreement and its appendices which form an integral part of this Agreement and are incorporated
herein by reference, represents the entire agreement of the parties relating to the subject matter. The General Terms and Conditions
of each party shall not apply to this Agreement.



 


		16.5	Any amendments to this Agreement or, the appendices may only be made by mutual agreement of the
parties, and must be in writing and executed by both parties.



 


		16.6	Any expiration or termination of this Agreement shall not release the parties from liabilities
or obligations accrued as of the date thereof.



 


		16.7	This Agreement shall not be assigned by Innocoll or PIONEER to any third party without the prior
written consent of the other Party.



 


		16.8	This Agreement has been prepared in the English language, and English shall control its interpretation
and meaning.



 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the Effective Date.


 


	PIONEER Limited	 	Innocoll Pharmaceuticals Limited
	 	 	 
	/s/ XinZhou Li	 	/s/ Michael Myers
	XinZhou Li	 	Michael Myers
	President and CEO	 	President and CEO


 




    	9



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


Exhibit A: Products


 


CollaGUARD Adhesion Barrier


 




    	10



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


Exhibit B: Prices
& Conditions


 


	Supply Price (€)
	Unit Size	 	 	Unit
                                         Price	 
	***	 	 	***	 
	***	 	 	***	 
	***	 	 	***	 
	***	 	 	***	 






***


 


Fully Recoverable License Fee:


 


***


 


Interest.


 


***


 




    	11



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


Exhibit C: Minimum
Annual Purchase Requirements


 


***


 




    	12



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


AMENDMENT TO COLLAGUARD LICENSING

MANUFACTURING AND SUPPLY AGREEMENT

between

PIONEER PHARMA COMPANY, LIMITED

AND INNOCOLL PHARMACEUTICALS LIMITED


 


THIS AMENDMENT (“Amendment”) to
that certain LICENSING, MANUFACTURING AND SUPPLY AGREEMENT by and among Pioneer Pharma Company, a limited liability company organized
and existing under the laws of the Republic of China (“Pioneer”), and Innocoll Pharmaceuticals Limited, a limited
liability company organized and existing under the laws of Ireland (“‘Innocoll”), dated as of October
12, 2011 (“Agreement”) is entered into between Pioneer and Innocoll effective as of August 6, 2012.


 


PRELIMINARY STATEMENTS:


 


		A.	Pioneer and Innocoll entered into the Agreement effective October 12, 2011, and will
expire, by its terms on October 12, 2021.



 


		B.	The parties desire to amend the territory and License Fees as set forth in this Amendment.



 


NOW, THEREFORE,
IN CONSIDERATION of the covenants and mutual promises contained herein, the receipt and sufficiency of which hereby are acknowledged,
the parties hereby agree as follows:


 


TERMS AND CONDITIONS:


 


1.          Definitions. To the extent
not otherwise defined in this Amendment, all capitalized terms shall have the meaning ascribed to them in the Agreement.


 


2.          Section 1.4. Territory
shall be amended to mean The People’s Republic of China, including the territories of Hong Kong, Macau, and Taiwan, Vietnam,
Cambodia, Malaysia, Singapore, Indonesia, Brunei Darussalam, Laos, Myanmar.


 


3.          License Fees: In consideration
of the expansion of the Territory to include the additional countries listed above, Pioneer shall make the following payments:


 


		·	***



 


		·	***



 


		·	***



 


		4.	General.



 


a.          Amendment
Controls. Notwithstanding anything to the contrary set forth in the Agreement, in the event of a conflict between the terms
of the Agreement and this Amendment, this Amendment shall control.


 


b.          Continuing
Effect of Other Terms of Licensing Manufacturing and Supply Agreement. Except as amended in this Amendment, all terms and conditions
of the Agreement shall remain in full force and effect.


 




    	13



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


c.          Counterparts.
This Amendment may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of
which together shall be one and the same instrument.


 


d.          Choice of
Law. The parties expressly agree that this Amendment shall be governed the substantive laws of Singapore without giving effect
to that jurisdiction’s choice of law rules.


 


e.          Submission
to Jurisdiction. The parties agree to submit to the non-exclusive jurisdiction of any competent court in Singapore with respect
to any matter arising out of this Amendment.


 


IN WITNESS WHEREOF, the parties by their
duly authorized officers have executed this Amendment on the date set forth below their signatures below, to be effective as of
August 6, 2012.


 


PIONEER PHARMA COMPANY LIMITED


 


	Signature:	/s/ XinZhou Li	 



 


	Name:	XinZhou Li	 



 


	Title:	President and CEO	 



 


	Date:	August 13, 2012	 


 


	INNOCOLL PHARMACEUTICALS LIMITED	 
	 	 
	Signature:	 /s/ Denise Carter	 



 


	Name:	 Denise Carter	 



 


	Title:	Vice President, Business Dev.	 



 


	Date:	 August 7, 2012	 


 




    	14